Xometry (NASDAQ:XMTR – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.19 by $0.09, FiscalAI reports. Xometry had a negative return on equity of 2.88% and a negative net margin of 3.82%. The firm had revenue of $252.44 million during the quarter, compared to analysts’ expectations of $235.54 million. During the same period in the previous year, the business earned $0.11 earnings per share. The firm’s revenue for the quarter was up 39.5% on a year-over-year basis.
Xometry Price Performance
Xometry stock opened at $95.49 on Tuesday. The company has a current ratio of 3.21, a quick ratio of 3.20 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average price of $96.37 and a 200 day moving average price of $76.22. Xometry has a 12-month low of $35.86 and a 12-month high of $112.94. The stock has a market cap of $4.95 billion, a P/E ratio of -159.15 and a beta of 1.23.
Insider Buying and Selling
In other news, Director Fabio Rosati sold 8,100 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $91.45, for a total value of $740,745.00. Following the completion of the sale, the director owned 93,567 shares of the company’s stock, valued at $8,556,702.15. This represents a 7.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Emily Rollins sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $84.31, for a total transaction of $421,550.00. Following the sale, the director owned 15,136 shares of the company’s stock, valued at $1,276,116.16. This represents a 24.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 64,699 shares of company stock worth $6,169,735 over the last ninety days. 9.10% of the stock is currently owned by insiders.
Analysts Set New Price Targets
A number of brokerages have recently commented on XMTR. Citizens Jmp reiterated a “market outperform” rating and issued a $120.00 target price on shares of Xometry in a research report on Monday, September 21st. The Goldman Sachs Group boosted their price target on shares of Xometry from $78.00 to $104.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. UBS Group upped their price objective on shares of Xometry from $88.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Citigroup reiterated a “market outperform” rating on shares of Xometry in a report on Monday, September 21st. Finally, Rosenblatt Securities raised their target price on shares of Xometry from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, September 22nd. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $113.18.
View Our Latest Research Report on Xometry
About Xometry
Xometry, Inc (NASDAQ:XMTR) operates a technology-driven marketplace that connects businesses seeking custom parts with a network of manufacturing suppliers. Its platform uses automated pricing, manufacturability analysis and digital workflows to help customers source parts and manage production more efficiently.
The company supports a range of manufacturing processes, including CNC machining, 3D printing, sheet metal fabrication, injection molding, urethane casting and other specialized production services.
See Also
- Five stocks we like better than Xometry
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
Receive News & Ratings for Xometry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xometry and related companies with MarketBeat.com's FREE daily email newsletter.
